TGF-β and cancer

Microbes and Infection

Volumn 1, Issue 15, 1999, Pages 1327-1347

  Reiss, Michael ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Smad; TGF

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER INVASION; CARCINOGENESIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; GENE SWITCHING; HUMAN; IMMUNOPHENOTYPING; IMMUNOREGULATION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

MUS MUSCULUS;

EID: 0033377548     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(99)00251-8     Document Type: Review

References (276)

1. Roberts A.B., Sporn M.B. Physiological actions and clinical applications of transforming growth factor-beta (TGF - beta). Growth Factors. 8:1993;1-9.
2. Weinberg R.A. The cat and mouse games that genes viruses and cells play. Cell. 88:1997;573-575.
3. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 88:1997;593-602.
4. Rozenblum E., Schutte M., Goggins M., Hahn S.A., Panzer S., Zahurak M., Goodman S.N., Sohn T.A., Hruban R.H., Yeo C.J., Kern S.E. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 57:1997;1731-1734.
5. Sporn M.B., Roberts A.B., Wakefield L.M., Glick A.B., Danielpour D. Transforming growth factor-beta and suppression of carcinogenesis. Princess Takamatsu Symp. 20:1989;259-266.
6. Markowitz S.D., Roberts A.B. Tumor suppressor activity of the TGF - beta pathway in human cancers. Cytokine Growth Factor Rev. 7:1996;93-102.
7. Pierce Jr D.F., Gorska A.E., Chytil A., Meise K.S., Page D.L., CoffeyJr R.J., Moses H.L. Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc. Natl. Acad. Sci. USA. 92:1995;4254-4258.
8. Kulkarni A.B., Huh C.G., Becker D., Geiser A., Lyght M., Flanders K.C., Roberts A.B., Sporn M.B., Ward J.M., Karlsson S. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA. 90:1993;770-774.
9. Glick A.B., Lee M.M., Darwiche N., Kulkarni A.B., Karlsson S., Yuspa S.H. Targeted deletion of the TGF - beta 1 gene causes rapid progression to squamous cell carcinoma. Genes Dev. 8:1994;2429-2440.
10. Dickson M.C., Martin J.S., Cousins F.M., Kulkarni A.B., Karlsson S., Akhurst R.J. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development. 121:1995;1845-1854.
11. Tang B., Böttinger E.P., Jakowlew S.B., Bagnall K.M., Mariano J., Anver M.R., Letterio J.J., Wakefield L.M. Transforming growth factor-β1 is a new form of tumor suppressor with true haploid insufficiency. Nature M. 4:1998;802-807.
12. Shida N., Ikeda H., Yoshimoto T., Oshima M., Taketo M.M., Miyoshi I. Estrogen-induced tumorigenesis in the pituitary gland of TGF - beta (+/-) knockout mice. Biochim. Biophys. Acta. 1407:1998;79-83.
13. Thorup I. Histomorphological and immunohistochemical characterization of colonic aberrant crypt foci in rats relationship to growth factor expression. Carcinogenesis. 18:1997;465-472.
14. Wu S.P., Theodorescu D., Kerbel R.S., Willson J.K., Mulder K.M., Humphrey L.E., Brattain M.G. TGF - beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J. Cell Biol. 116:1992;187-196.
15. Wu S.P., Sun L.Z., Willson J.K., Humphrey L., Kerbel R., Brattain M.G. Repression of autocrine transforming growth factor beta 1 and beta 2 in quiescent CBS colon carcinoma cells leads to progression of tumorigenic properties. Cell Growth Differ. 4:1993;115-123.
16. Wang X.J., Greenhalgh D.A., Bickenbach J.R., Jiang A., Bundman D.S., Krieg T., Derynck R., Roop D.R. Expression of a dominant-negative type II transforming growth factor β (TGF-β) receptor in the epidermis of transgenic mice blocks TGF-β-mediated growth inhibition. Proc. Natl. Acad. Sci. USA. 94:1997;2386-2391.
17. Jakubczak J., Böttinger E., Haines D., Merlino G., Wakefield L. Enhanced mammary tumorigenesis in transgenic mice expressing a dominant negative type II TGF-β receptor under the control of the MMTV-LTR. Proc. Am. Assoc. Cancer Res. 38:1997;580.
18. Pasche B., Luo Y., Rao P.H., Nimer S.D., Dmitrovsky E., Caron P., Luzzatto L., Offit K., Cordon-Cardo C., Renault B., Satagopan J.M., Murty V.V., Massague J. Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. Cancer Res. 58:1998;2727-2732.
19. Chen T., DeVries E.G.E., Hollema H., Yegen H.A., Vellucci V.F., Strickler H.D., Hildesheim A., Reiss M. Structural alterations of transforming growth factor-β receptor genes in cervical carcinoma. Int. J. Cancer. 82:1999;43-51.
20. Zhu Y., Richardson J.A., Parada L.F., Graff J.M. Smad3 mutant mice develop metastatic colorectal cancer. Cell. 94:1998;703-714.
21. Takaku K., Oshima M., Miyoshi H., Matsui M., Seldin M.F., Taketo M.M. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell. 92:1998;645-656.
22. Sirard C., De LaPompa J.L., Elia A., Itie A., Mirtsos C., Cheung A., Hahn S., Wakeham A., Schwartz L., Kern S.E., Rossant J., Mak T.W. The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryo. Genes Dev. 12:1998;107-119.
23. Reiss M., Santoro V., DeJonge R.R., Vellucci V.F. Transfer of chromosome 18 into human head and neck squamous carcinoma cells Evidence for tumor suppression by Smad4/DPC4. Cell Growth Diff. 8:1997;407-415.
24. Grau A.M., Zhang L., Wang W., Ruan S., Evans D.B., Abbruzzese J.L., Zhang W., Chiao P.J. Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res. 57:1997;3929-3934.
25. Hunt K.K., Fleming J.B., Abramian A., Zhang L., Evans D.B., Chiao P.J. Overexpression of tumor suppressor gene Smad4/DPC4 induces p21waf1 expression and agrowth inhibition in human carcinoma cells. Cancer Res. 58:1998;5656-5661.
26. Zhou S., Buckhaults P., Zawel L., Bunz F., Riggins G., LeDai J., Kern S.E., Kinzler K.W., Vogelstein B. Targeted deletion of smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells [In Process Citation]. Proc. Natl. Acad. Sci. USA. 95:1998;2412-2416.
27. DeLarco J.E., Todaro G.J. Growth factors from murine sarcoma virus-transformed cells. Proc. Natl. Acad. Sci. USA. 75:1978;4001-4005.
28. Corcione A., Roncella S., Cutrona G., Mori P.G., Ferrarini M., Pistoia V. Transforming growth factor beta-1 (TGF - beta 1) released by an Epstein-Barr virus (EBV) positive spontaneous lymphoblastoid cell line from a patient with Kostmann's congenital neutropenia inhibits the growth of normal committed haemopoietic progenitors in vitro. Br. J. Haematol. 85:1993;684-691.
29. Cupp C., Taylor J.P., Khalili K., Amini S. Evidence for stimulation of the transforming growth factor beta 1 promoter by HIV-1 Tat in cells derived from CNS. Oncogene. 8:1993;2231-2236.
30. Michelson S., Alcami J., Kim S.J., Danielpour D., Bachelerie F., Picard L., Bessia C., Paya C., Virelizier J.L. Human cytomegalovirus infection induces transcription and secretion of transforming growth factor beta 1. J. Virol. 68:1994;5730-5737.
31. Cayrol C., Flemington E.K. Identification of cellular target genes of the Epstein-Barr virus transactivator Zta activation of transforming growth factor beta igh3 (TGF - beta igh3) and TGF - beta 1. J. Virol. 69:1995;4206-4212.
32. Schultz-Cherry S., Hinshaw V.S. Influenza virus neuraminidase activates latent transforming growth factor beta. J. Virol. 70:1996;8624-8629.
33. Yoo Y.D., Ueda H., Park K., Flanders K.C., Lee Y.I., Jay G., Kim S.J. Regulation of transforming growth factor-beta 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis. J. Clin. Invest. 97:1996;388-395.
34. Dey A., Atcha I.A., Bagchi S. HPV 16 E6 oncoprotein stimulates the Transforming Growth Factor-beta-1 promoter In fibroblasts through a specific GC-rich sequence. Virology. 228:1997;190-199.
35. Creek K.E., Geslani G., Batova A., Pirisi L. Progressive loss of sensitivity to growth control by retinoic acid and transforming growth factor-beta at late stages of human papillomavirus type 16-initiated transformation of human keratinocytes. Adv. Exp. Med. Biol. 375:1995;117-135.
36. Roberts A.B., Frolik C.A., Anzano M.A., Sporn M.B. Transforming growth factors from neoplastic and nonneoplastic tissues. Fed. Proc. 42:1983;2621-2626.
37. Nishimura R., Okumura H., Noda K., Yasumitsu H., Umeda M. High level of beta-type transforming growth factor activity in human urine obtained from cancer patients Jpn J. Cancer Res. 77:1986;560-567.
38. Tsushima H., Kawata S., Tamura S., Ito N., Shirai Y., Kiso S., Imai Y., Shimomukai H., Nomura Y., Matsuda Y., Matsuzawa Y. High levels of transforming growth factor beta 1 in patients with colorectal cancer association with disease progression. Gastroenterology. 110:1996;375-382.
39. Perry K.T., Anthony C.T., Case T., Steiner M.S. Transforming growth factor beta as a clinical biomarker for prostate cancer. Urology 49. 1997;151-155.
40. Kong F.M., Anscher M.S., Murase T., Abbott B.D., Iglehart J.D., Jirtle R.L. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann. Surg. 222:1995;155-162.
41. Chopra V., Dinh T.V., Hannigan E.V. Serum levels of interleukins growth factors and angiogenin in patients with endometrial cancer. J. Cancer Res. Clin. Oncol. 123:1997;167-172.
42. Sminia P., Barten A.D., Van Waarde M.A., Vujaskovic Z., VanTienhoven G. Plasma transforming growth factor beta levels in breast cancer patients. Oncol. Rep. 5:1998;485-488.
43. Maccallum J., Bartlett J.M., Thompson A.M., Keen J.C., Dixon J.M., Miller W.R. Expression of transforming growth factor beta mRNA isoforms in human breast cancer [see comments]. Br. J. Cancer. 69:1994;1006-1009.
44. Travers M.T., Barrett-Lee P.J., Berger U., Luqmani Y.A., Gazet J.C., Powles T.J., Coombes R.C. Growth factor expression in normal benign and malignant breast tissue. Br. Med. J. (Clin. Res. Ed). 296:1988;1621-1624.
45. Walker R.A., Dearing S.J. Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur. J. Cancer. 28:1992;641-644.
46. McCune B.K., Mullin B.R., Flanders K.C., Jaffurs W.J., Mullen L.T., Sporn M.B. Localization of transforming growth factor-beta isotypes in lesions of the human breast [see comments]. Hum. Pathol. 23:1992;13-20.
47. Dalal B.I., Keown P.A., Greenberg A.H. Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am. J. Pathol. 143:1993;381-389.
48. Auvinen P., Lipponen P., Johansson R., Syrjanen K. Prognostic significance of TGF - beta 1 and TGF - beta 2 expressions in female breast cancer. Anticancer Res. 15:1995;2627-2631.
49. De Jong J.S., Van Diest P.J., Van DerValk P., Baak J.P. Expression of growth factors growth inhibiting factors and their receptors in invasive breast Cancer I An inventory in search of autocrine and paracrine loops. J. Pathol. 184:1998;44-52.
50. Gorsch S.M., Memoli V.A., Stukel T.A., Gold L.I., Arrick B.A. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res. 52:1992;6949-6952.
51. Hirayama D., Fujimori T., Satonaka K., Nakamura T., Kitazawa S., Horio M., Maeda S., Nagasako K. Immunohistochemical study of epidermal growth factor and transforming growth factor-beta in the penetrating type of early gastric cancer. Hum. Pathol. 23:1992;681-685.
52. Mizoi T., Ohtani H., Miyazono K., Miyazawa M., Matsuno S., Nagura H. Immunoelectron microscopic localization of transforming growth factor beta 1 and latent transforming growth factor beta 1 binding protein in human gastrointestinal carcinomas qualitative difference between cancer cells and stromal cells. Cancer Res. 53:1993;183-190.
53. Kai T., Taketazu F., Kawakami M., Shimanuki K., Yamada S., Miyazono K., Kato M., Miyata M. Distribution of transforming growth factor-beta and its receptors in gastric carcinoma tissue. Jpn J. Cancer Res. 87:1996;296-304.
54. Morisaki T., Katano M., Ikubo A., Anan K., Nakamura M., Nakamura K., Sato H., Tanaka M., Torisu M. Immunosuppressive cytokines (IL-10 TGF - beta) genes expression in human gastric carcinoma tissues. J. Surg. Oncol. 63:1996;234-239.
55. Naef M., Ishiwata T., Friess H., Buchler M.W., Gold L.I., Korc M. Differential localization of transforming growth factor-beta isoforms in human gastric mucosa and overexpression in gastric carcinoma. Int. J. Cancer. 71:1997;131-137.
56. Mahara K., Kato J., Terui T., Takimoto R., Horimoto M., Murakami T., Mogi Y., Watanabe N., Kohgo Y., Niitsu Y. Transforming growth factor beta 1 secreted from scirrhous gastric cancer cells is associated with excess collagen deposition in the tissue. Br. J. Cancer. 69:1994;777-783.
57. Ura H., Obara T., Yokota K., Shibata Y., Okamura K., Namiki M. Effects of transforming growth factor-beta released from gastric carcinoma cells on the contraction of collagen-matrix gels containing fibroblasts. Cancer Res. 51:1991;3550-3554.
58. Yashiro M., Chung Y.S., Nishimura S., Inoue T., Sowa M. Establishment of two new scirrhous gastric cancer cell lines analysis of factors associated with disseminated metastasis. Br. J. Cancer. 72:1995;1200-1210.
59. Yashiro M., Chung Y.S., Kubo T., Hato F., Sowa M. Differential responses of scirrhous and well-differentiated gastric cancer cells to orthotopic fibroblasts. Br. J. Cancer. 74:1996;1096-1103.
60. Inoue T., Chung Y.S., Yashiro M., Nishimura S., Hasuma T., Otani S., Sowa M. Transforming growth factor-beta and hepatocyte growth factor produced by gastric fibroblasts stimulate the invasiveness of scirrhous gastric cancer cells. Jpn J. Cancer Res. 88:1997;152-159.
61. Cardillo M.R., Yap E.P. TGF - beta 1 in colonic neoplasia. A genetic molecular and immunohistochemical study. Arch. Anat. Cytol. Pathol. 44:1996;241-249.
62. Picon A., Gold L.I., Wang J., Cohen A., Friedman E. A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta1. Cancer Epidemiol. Biomarkers Prev. 7:1998;497-504.
63. Merz V.W., Arnold A.M., Studer U.E. Differential expression of transforming growth factor-beta 1 and beta 3 as well as c-fos mRNA in normal human prostate benign prostatic hyperplasia and prostatic cancer. World J. Urol. 12:1994;96-98.
64. Truong L.D., Kadmon D., McCune B.K., Flanders K.C., Scardino P.T., Thompson T.C. Association of transforming growth factor-beta 1 with prostate cancer an immunohistochemical study. Hum. Pathol. 24:1993;4-9.
65. Eastham J.A., Truong L.D., Rogers E., Kattan M., Flanders K.C., Scardino P.T., Thompson T.C. Transforming growth factor-beta 1 comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab. Invest. 73:1995;628-635.
66. Eklov S., Funa K., Nordgren H., Olofsson A., Kanzaki T., Miyazono K., Nilsson S. Lack of the latent transforming growth factor beta binding protein in malignant but not benign prostatic tissue. Cancer Res. 53:1993;3193-3197.
67. Miyamoto H., Kubota Y., Shuin T., Torigoe S., Dobashi Y., Hosaka M. Expression of transforming growth factor-beta 1 in human bladder cancer. Cancer. 75:1995;2565-2570.
68. Eder I.E., Stenzl A., Hobisch A., Cronauer M.V., Bartsch G., Klocker H. Expression of transforming growth factors beta-1 beta 2 and beta 3 in human bladder carcinomas. Br. J. Cancer. 75:1997;1753-1760.
69. Gold L.I., Saxena B., Mittal K.R., Marmor M., Goswami S., Nactigal L., Korc M., Demopoulos R.I. Increased expression of transforming growth factor beta isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium evidence for paracrine and autocrine action. Cancer Res. 54:1994;2347-2358.
70. Comerci Jr J.T., Runowicz C.D., Flanders K.C., DeVictoria C., Fields A.L., Kadish A.S., Goldberg G.L. Altered expression of transforming growth factor-beta 1 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix. Cancer. 77:1996;1107-1114.
71. Kloen P., Gebhardt M.C., Perez-Atayde A., Rosenberg A.E., Springfield D.S., Gold L.I., Mankin H.J. Expression of transforming growth factor-beta (TGF - beta) isoforms in osteosarcomas TGF - beta3 is related to disease progression. Cancer. 80:1997;2230-2239.
72. Bottinger E.P., Jakubczak J.L., Roberts I.S., Mumy M., Hemmati P., Bagnall K., Merlino G., Wakefield L.M. Expression of a dominant-negative mutant TGF - beta type II receptor in transgenic mice reveals essential roles for TGF - beta in regulation of growth and differentiation in the exocrine pancreas. Embo J. 16:1997;2621-2633.
73. Friedman E., Gold L.I., Klimstra D., Zeng Z.S., Winawer S., Cohen A. High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol. Biomarkers Prev. 4:1995;549-554.
74. Doran T., Stuhlmiller H., Kim J.A., Martin Jr E.W., Triozzi P.L. Oncogene and cytokine expression of human colorectal tumors responding to immunotherapy. J. Immunother. 20:1997;372-376.
75. Friess H., Yamanaka Y., Buchler M., Ebert M., Beger H.G., Gold L.I., Korc M. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology. 105:1993;1846-1856.
76. Takanami I., Tanaka F., Hashizume T., Kodaira S. Roles of the transforming growth factor beta 1 and its type I and II receptors in the development of a pulmonary adenocarcinoma results of an immunohistochemical study. J. Surg. Oncol. 64:1997;262-267.
77. Kim I.Y., Ahn H.J., Lang S., Oefelein M.G., Oyasu R., Kozlowski J.M., Lee C. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clin. Cancer Res. 4:1998;1625-1630.
78. Murray P.A., Barrett-Lee P., Travers M., Luqmani Y., Powles T., Coombes R.C. The prognostic significance of transforming growth factors in human breast cancer. Br. J. Cancer. 67:1993;1408-1412.
79. Welch D.R., Fabra A., Nakajima M. Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc. Natl. Acad. Sci. USA. 87:1990;7678-7682.
80. Arrick B.A., Lopez A.R., Elfman F., Ebner R., Damsky C.H., Derynck R. Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor β1. J. Cell Biol. 118:1992;715-726.
81. Ueki N., Ohkawa T., Yokoyama Y., Maeda J., Kawai Y., Ikeda T., Amuro Y., Hada T., Higashino K. Potentiation of metastatic capacity by transforming growth factor-beta 1 gene transfection. Jpn J. Cancer Res. 84:1993;589-593.
82. Oshima M., Oshima H., Taketo M.M. TGF - beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev. Biol. 179:1996;297-302.
83. Mc Allister K.A., Grogg K.M., Johnson D.W., Gallione C.J., Baldwin M.A., Jackson C.E., Helmbold E.A., Markel D.S., McKinnon W.C., Murrell J. Endoglin a TGF - beta binding protein of endothelial cells is the gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet. 8:1994;345-351.
84. McAllister K.A., Baldwin M.A., Thukkani A.K., Gallione C.J., Berg J.N., Porteous M.E., Guttmacher A.E., Marchuk D.A. Six novel mutations in the endoglin gene in hereditary hemorrhagic telangiectasia type 1 suggest a dominant-negative effect of receptor function. Hum. Mol. Genet. 4:1995;1983-1985.
85. Johnson D.W., Berg J.N., Baldwin M.A., Gallione C.J., Marondel I., Yoon S.J., Stenzel T.T., Speer M., Pericak-Vance M.A., Diamond A., Guttmacher A.E., Jackson C.E., Attisano L., Kucherlapati R., Porteous M.E., Marchuk D.A. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat. Genet. 13:1996;189-195.
86. Pepper M.S. Transforming growth factor-beta vasculogenesis angiogenesis and vessel wall integrity. Cytokine Growth Factor Rev. 8:1997;21-43.
87. Ueki N., Nakazato M., Ohkawa T., Ikeda T., Amuro Y., Hada T., Higashino K. Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis validity of neutralizing antibodies to block tumor growth. Biochim. Biophys. Acta. 1137:1992;189-196.
88. De Jong J.S., Van Diest P.J., Van DerValk P., Baak J.P. Expression of growth factors growth-inhibiting factors and their receptors in invasive breast Cancer II Correlations with proliferation and angiogenesis. J. Pathol. 184:1998;53-57.
89. Nakanishi Y., Kodama J., Yoshinouchi M., Tokumo K., Kamimura S., Okuda H., Kudo T. The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer. Int. J. Gynecol. Pathol. 16:1997;256-262.
90. Choi Y.H., Choi K.C., Park Y.E. Relationship of transforming growth factor beta 1 to angiogenesis in gastric carcinoma. J. Korean Med. Sci. 12:1997;427-432.
91. Merwin J.R., Erson J.M., Kocher O., VanItallie C.M., Madri J.A. Transforming growth factor beta 1 modulates extracellular matrix organization and cell-cell junctional complex formation during in vitro angiogenesis. J. Cell Physiol. 142:1990;117-128.
92. Sankar S., Mahooti-Brooks N., Bensen L., McCarthy T.L., Centrella M., Madri J.A. Modulation of transforming growth factor beta receptor levels on microvascular endothelial cells during in vitro angiogenesis. J. Clin. Invest. 97:1996;1436-1446.
93. O'Mahony C.A., Albo D., Tuszynski G.P., Berger D.H. Transforming growth factor-beta 1 inhibits generation of angiostatin by human pancreatic cancer cells. Surgery. 124:1998;388-393.
94. Benefield J., Petruzzelli G.J., Fowler S., Taitz A., Kalkanis J., Young M.R. Regulation of the steps of angiogenesis by human head and neck squamous cell carcinomas. Invasion Metastasis. 16:1996;291-301.
95. Patel V.A., Hill D.J., Eggo M.C., Sheppard M.C., Becks G.P., Logan A. Changes in the immunohistochemical localisation of fibroblast growth factor-2 transforming growth factor-beta 1 and thrombospondin-1 are associated with early angiogenic events in the hyperplastic rat thyroid. J. Endocrinol. 148:1996;485-499.
96. Letterio J.J., Roberts A.B. TGF - beta a critical modulator of immune cell function. Clin. Immunol. Immunopathol. 84:1997;244-250.
97. Arteaga C.L., Hurd S.D., Winnier A.R., Johnson M.D., Fendly B.M., Forbes J.T. Anti-transforming growth factor (TGF-)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF - beta interactions in human breast cancer progression. J. Clin. Invest. 92:1993;2569-2576.
98. Fakhrai H., Dorigo O., Shawler D.L., Lin H., Mercola D., Black K.L., Royston I., Sobol R.E. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc. Natl. Acad. Sci. USA. 93:1996;2909-2914.
99. Shull M.M., Ormsby I., Kier A.B., Pawlowski S., Diebold R.J., Yin M., Allen R., Sidman C., Proetzel G., Calvin D. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 359:1992;693-699.
100. Borkowski T.A., Letterio J.J., Farr A.G., Udey M.C. A role for endogenous transforming growth factor beta 1 in Langerhans cell biology the skin of transforming growth factor beta 1 null mice is devoid of epidermal Langerhans cells. J. Exp. M. 184:1996;2417-2422.
101. Borkowski T.A., Letterio J.J., Mackall C.L., Saitoh A., Wang X.J., Roop D.R., Gress R.E., Udey M.C. A role for TGF-beta1 in langerhans cell biology. Further characterization of the epidermal Langerhans cell defect in TGF-beta1 null mice. J. Clin. Invest. 100:1997;575-581.
102. Borkowski T.A., Letterio J.J., Mackall C.L., Saitoh A., Farr A.G., Wang X.J., Roop D.R., Gress R.E., Udey M.C. Langerhans cells in the TGF- beta 1 null mouse. Adv. Exp. Med. Biol. 417:1997;307-310.
103. Tada T., Ohzeki S., Utsumi K., Takiuchi H., Muramatsu M., Li X.F., Shimizu J., Fujiwara H., Hamaoka T. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J. Immunol. 146:1991;1077-1082.
104. Torre-Amione G., Beauchamp R.D., Koeppen H., Park B.H., Schreiber H., Moses H.L., Rowley D.A. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA. 87:1990;1486-1490.
105. Weiskirch L.M., Bar-Dagan Y., Mokyr M.B. Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy. Cancer Immunol. Immunother. 38:1994;215-224.
106. Jachimczak P., Bogdahn U., Schneider J., Behl C., Meixensberger J., Apfel R., Dorries R., Schlingensiepen K.H., Brysch W. The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J. Neurosurg. 78:1993;944-951.
107. Jachimczak P., Hessdorfer B., Fabel-Schulte K., Wismeth C., Brysch W., Schlingensiepen K.H., Bauer A., Blesch A., Bogdahn U. Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int. J. Cancer. 65:1996;332-337.
108. Park J.A., Wang E., Kurt R.A., Schluter S.F., Hersh E.M., Akporiaye E.T. Expression of an antisense Transforming Growth Factor-Beta-1 transgene reduces tumorigenicity of EMT6 mammary tumor cells. Cancer Gene Therapy. 4:1997;42-50.
109. Tzai T.S., Lin C.I., Shiau A.L., Wu C.L. Antisense oligonucleotide specific for transforming growth factor-beta 1 inhibit both in vitro and in vivo growth of MBT-2 murine bladder cancer. Anticancer Res. 18:1998;1585-1589.
110. Munger J.S., Harpel J.G., Gleizes P.E., Mazzieri R., Nunes I., Rifkin D.B. Latent transforming growth factor-beta structural features and mechanisms of activation. Kidney Int. 51:1997;1376-1382.
111. Miyazono K., Hellman U., Wernstedt C., Heldin C.H. Latent high molecular weight complex of transforming growth factor-β from human platelets; a high molecular weight complex containing precursor sequences. J. Biol. Chem. 263:1988;6407-6415.
112. Massagué J. TGF - β signaling Receptors transducers and MAD proteins. Cell. 85:1996;947-950.
113. Valverius E.M., Walker-Jones D., Bates S.E., Stampfer M.R., Clark R., McCormick F., Dickson R.B., Lippman M.E. Production of and responsiveness to transforming growth factor-β in normal and oncogene-transformed human mammary epithelial cells. Cancer Res. 49:1989;6269-6274.
114. Arteaga C.L., Tandon A.K., VonHoff D.D., Osborne C.K. Transforming growth factor beta potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res. 48:1988;3898-3904.
115. Kalkhoven E., Kwakkenbos-Isbrucker L., Mummery C.L., Delaat S.W., Van Den Eijnden-Van Raaij A.J.M., Van Der Saag P.T., Van DerBurg B. The role of TGF - β production in growth inhibition of breast tumor cells by progestins. Int. J. Cancer. 61:1995;80-86.
116. Barcellos-Hoff M.H., Derynck R., Tsang M.L., Weatherbee J.A. Transforming growth factor-beta activation in irradiated murine mammary gland. J. Clin. Invest. 93:1994;892-899.
117. Ehrhart E.J., Segarini P., Tsang M.L., Carroll A.G., Barcellos-Hoff M.H. Latent transforming growth factor beta1 activation in situ quantitative and functional evidence after low-dose gamma-irradiation. Faseb J. 11:1997;991-1002.
118. Fowlis D.J., Flanders K.C., Duffie E., Balmain A., Akhurst R.J. Discordant localisation of TGF-β RNA and protein during chemical carcinogenesis in mouse skin. Cell Growth Differ. 3:1992;81-91.
119. Esherick J.S., Dicunto F., Flanders K.C., Missero C., Dotto G.P. Transforming growth factorβ1 induction is associated with transforming growth factorβ2 and β3 down-modulation in 12-O-tetradecanoylphorbol-13-acetate-induced skin hyperplasia. Cancer Res. 53:1993;5507-5512.
120. Jirtle R.L., Haag J.D., Ariazi E.A., Gould M.N. Increased mannose 6-phosphate/insulin-like growth factor II receptor and transforming growth factor beta 1 levels during monoterpene-induced regression of mammary tumors. Cancer Res. 53:1993;3849-3852.
121. Mansbach J.M., Mills J.J., Boyer I.J., DeSouza A.T., Hankins G.R., Jirtle R.L. Phenobarbital selectively promotes initiated cells with reduced TGF- beta receptor levels. Carcinogenesis. 17:1996;171-174.
122. Crawford S.E., Stellmach V., Murphy-Ullrich J.E., Ribeiro S.M.F., Lawler J., Hynes R.O., Boivin G.P., Bouck N. Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell. 93:1998;1159-1170.
123. Schultz-Cherry S., Murphy-Ullrich J.E. Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism [published erratum appears in J. Cell Biol. (1993) Sep; 122 (5) following 1143]. J. Cell Biol. 122:1993;923-932.
124. Schultz-Cherry S., Ribeiro S., Gentry L., Murphy-Ullrich J.E. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J. Biol. Chem. 269:1994;26775-26782.
125. Schultz-Cherry S., Lawler J., Murphy-Ullrich J.E. The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. J. Biol. Chem. 269:1994;26783-26788.
126. Penttinen R.P., Kobayashi S., Bornstein P. Transforming growth factor beta increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability. Proc. Natl. Acad. Sci. USA. 85:1988;1105-1108.
127. Schultz-Cherry S., Chen H., Mosher D.F., Misenheimer T.M., Krutzsch H.C., Roberts D.D., Murphy-Ullrich J.E. Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J. Biol. Chem. 270:1995;7304-7310.
128. Guo N.H., Krutzsch H.C., Inman J.K., Shannon C.S., Roberts D.D. Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1. J. Pept. Res. 50:1997;210-221.
129. Guo N., Krutzsch H.C., Inman J.K., Roberts D.D. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res. 57:1997;1735-1742.
130. Raychaudhury A., Frazier W.A., D'Amore P.A. Comparison of normal and tumorigenic endothelial cells differences in thrombospondin production and responses to transforming growth factor-beta. J. Cell Sci. 107:1994;39-46.
131. Sheibani N., Frazier W.A. Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis. Proc. Natl. Acad. Sci. USA. 92:1995;6788-6792.
132. Roberts D.D. Regulation of tumor growth and metastasis by thrombospondin-1. Faseb J. 10:1996;1183-1191.
133. Hsu S.C., Volpert O.V., Steck P.A., Mikkelsen T., Polverini P.J., Rao S., Chou P., Bouck N.P. Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res. 56:1996;5684-5691.
134. Fynan T.M., Reiss M. Resistance to inhibition of cell growth by Transforming Growth Factor-β and its role in oncogenesis. Crit. Rev. Oncogenesis. 4:1993;493-540.
135. Rodeck U., Bossler A., Graeven U., Fox F.E., Nowell P.C., Knabbe C., Kari C. Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res. 54:1994;575-581.
136. Hurteau J., Rodriguez G.C., Whitaker R.S., Shah S., Mills G., Bast R.C., Berchuck A. Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer. 74:1994;93-99.
137. Havrilesky L.J., Hurteau J.A., Whitaker R.S., Elbendary A., Wu S., Rodriguez G.C., BastJr R.C., Berchuck A. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta. Cancer Res. 55:1995;944-948.
138. Taetle R., Payne C., Dos S.B., Russell M., Segarini P. Effects of transforming growth factor beta 1 on growth and apoptosis of human acute myelogenous leukemia cells. Cancer Res. 53:1993;3386-3393.
139. Haddow S., Fowlis D.J., Parkinson K., Akhurst R.J., Balmain A. Loss of growth control by TGF - beta occurs at a late stage of mouse skin carcinogenesis and is independent of ras gene activation. Oncogene. 6:1991;1465-1470.
140. Missero C., Ramon Y., Cajal R., Dotto G.P. Escape from transforming growth factor b control and oncogene cooperation in skin tumor development. Proc. Natl. Acad. Sci. USA. 88:1991;9613-9617.
141. Boukamp P., Peter W., Pascheberg U., Altmeier S., Fasching C., Stanbridge E.J., Fusenig N.E. Step-wise progression in human skin carcinogenesis in vitro involves mutational inactivation of p53 rasH oncogene activation and additional chromosome loss. Oncogene. 11:1995;961-969.
142. Manning A.M., Williams A.C., Game S.M., Paraskeva C. Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor beta (TGF - beta) conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-beta. Oncogene. 6:1991;1471-1476.
143. Hague A., Manning A.M., Van DerStappen J.W., Paraskeva C. Escape from negative regulation of growth by transforming growth factor beta and from the induction of apoptosis by the dietary agent sodium butyrate may be important in colorectal carcinogenesis. Cancer Metastasis Rev. 12:1993;227-237.
144. DeGeest K., Bergman C.A., Turyk M.E., Frank B.S., Wilbanks G.D. Differential response of cervical intraepithelial and cervical carcinoma cell lines to Transforming Growth Factor-β1. Gyn. Oncol. 55:1994;376-385.
145. Markowitz S.D., Myeroff L., Cooper M.J., Traicoff J., Kochera M., Lutterbaugh J., Swiriduk M., Willson J.K. A benign cultured colon adenoma bears three genetically altered colon cancer oncogenes but progresses to tumorigenicity and transforming growth factor-beta independence without inactivating the p53 tumor suppressor gene. J. Clin. Invest. 93:1994;1005-1013.
146. Kadin M.E., Cavaille-Coll M.W., Gertz R., Massagué J., Cheifetz S., George D. Loss of receptors for transforming growth factor β in human T-cell malignancies. Proc. Natl. Acad. Sci. USA. 91:1994;6002-6006.
147. Capocasale R.J., Lamb R.J., Vonderheid E.C., Fox F.E., Rook A.H., Nowell P.C., Moore J.S. Reduced surface expression of transforming growth factor β receptor type II in mitogen-activated T-cells from Sézary patients. Proc. Natl. Acad. Sci. USA. 92:1995;5501-5505.
148. Knaus P.I., Lindemann D., Decoteau J.F., Perlman R., Yankelev H., Hille M., Kadin M.E., Lodish H.F. A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma. Mol. Cell Biol. 16:1996;3480-3489.
149. Reiss M. Transforming growth factor-beta and cancer a love-hate relationship? Oncol Res. 9:1997;447-457.
150. Massague J., Weis-Garcia F. Serine/threonine kinase receptors mediators of transforming growth factor beta family signals. Cancer Surv. 27:1996;41-64.
151. Derynck R., Feng X.H. TGF - b receptor signaling. Biochim. Biophys. Acta. 1333:1997;F105-F150.
152. Saitoh M., Nishitoh M., Amagasa T., Miyazono K., Takagi M., Ichijo H. Identification of important regions in the cytoplasmic juxtamembrane domain of type I receptor that separate signaling pathways of Transforming Growth Factor-β J. Biol. Chem. 271:1996;2769-2775.
153. Kim I.Y., Ahn H.J., Zelner D.J., Shaw J.W., Sensibar J.A., Kim J.H., Kato M., Lee C. Genetic change in transforming growth factor beta (TGF - beta) receptor type I gene correlates with insensitivity to TGF - beta 1 in human prostate cancer cells. Cancer Res. 56:1996;44-48.
154. Kim I.Y., Zelner D.J., Lee C. The conventional transforming growth factor-beta (TGF - beta) receptor type I is not required for TGF - beta 1 signaling in a human prostate cancer cell line LNCaP. Exp. Cell Res. 241:1998;151-160.
155. Goggins M., Shekher M., Turnacioglu K., Yeo C.J., Hruban R.H., Kern S.E. Genetic alterations of the transforming growth factor β receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res. 58:1998;5329-5332.
156. Chen T., Carter D., Garrigue-Antar L., Reiss M. Transforming Growth Factor-β type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res. 58:1998;4805-4810.
157. Guo Y., Jacobs S.C., Kyprianou N. Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF - beta1) type I and type II receptors in human prostate cancer. Int. J. Cancer. 71:1997;573-579.
158. Baldwin R.L., Friess H., Yokoyama M., Lopez M.E., Kobrin M.S., Buchler M.W., Korc M. Attenuated ALK5 receptor expression in human pancreatic cancer correlation with resistance to growth inhibition. Int. J. Cancer. 67:1996;283-288.
159. Lu Z., Friess H., Graber H.U., Guo X., Schilling M., Zimmermann A., Korc M., Buchler M.W. Presence of two signaling TGF - beta receptors in human pancreatic cancer correlates with advanced tumor stage. Dig. Dis. Sci. 42:1997;2054-2063.
160. Baldwin R.L., Korc M. Growth inhibition of human pancreatic carcinoma cells by transforming growth factor beta-1. Growth Factors. 8:1993;23-34.
161. Kleeff J., Korc M. Up-regulation of transforming growth factor (TGF-)-beta receptors by TGF - beta1 in COLO-357 cells. J. Biol. Chem. 273:1998;7495-7500.
162. Wagner M., Kleeff J., Lopez M.E., Bockman I., Massaque J., Korc M. Transfection of the type I TGF - beta receptor restores TGF - beta responsiveness in pancreatic cancer. Int. J. Cancer. 78:1998;255-260.
163. Kimchi A., Wang X.F., Weinberg R.A., Cheifetz S., Massague J. Absence of TGF - beta receptors and growth inhibitory responses in retinoblastoma cells. Science. 240:1988;196-199.
164. Horie K., Yamashita H., Mogi A., Takenoshita S., Miyazono K. Lack of transforming growth factor-beta type II receptor expression in human retinoblastoma cells. J. Cell Physiol. 175:1998;305-313.
165. Park K., Kim S.J., Bang Y.J., Park J.G., Kim N.K., Roberts A.B., Sporn M.B. Genetic changes in the transforming growth factor beta (TGF - beta) type II receptor gene in human gastric cancer cells correlation with sensitivity to growth inhibition by TGF - beta. Proc. Natl. Acad. Sci. USA. 91:1994;8772-8776.
166. Sun L., Wu G., Willson J.K., Zborowska E., Yang J., Rajkarunanayake I., Wang J., Gentry L.E., Wang X.F., Brattain M.G. Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J. Biol. Chem. 269:1994;26449-26559.
167. Kalkhoven E., Roelen B.A., De Winter J.P., Mummery C.L., Van Den Eijnden-Van Raaij A.J., Van Der Saag P.T., Van DerBurg B. Resistance to transforming growth factor beta and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ. 6:1995;1151-1161.
168. De Jonge R.R., Garrigue-Antar L., Vellucci V.F., Reiss M. Frequent inactivation of the transforming growth factor beta type II receptor in small-cell lung carcinoma cells. Oncol. Res. 9:1997;89-98.
169. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J., Fan R.S., Zborowska E., Kinzler K.W., Vogelstein B. Inactivation of the type II TGF - beta receptor in colon cancer cells with microsatellite instability [see comments]. Science. 268:1995;1336-1338.
170. Myeroff L.L., Parsons R., Kim S.J., Hedrick L., Cho K.R., Orth K., Mathis M., Kinzler K.W., Lutterbaugh J., Park K., Bang Y.J., Lee H.Y., Park J.G., Lynch H.T., Roberts A.B., Vogelstein B., Markowitz S.D. A transforming growth factor β type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res. 55:1995;5545-5547.
171. Parsons R., Myeroff L.L., Liu B., Willson J.K.V., Markowitz S.D., Kinzler K.W., Vogelstein B. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res. 55:1995;5548-5550.
172. Wang J., Sun L., Myeroff L., Wang X., Gentry L.E., Yang J., Liang J., Zborowska E., Markowitz S., Willson J.K. Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J. Biol. Chem. 270:1995;22044-22049.
173. Lu S.L., Akiyama Y., Nagasaki H., Saitoh K., Yuasa Y. Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer. Biochem. Biophys. Res. Commun. 216:1995;452-457.
174. Abe T., Ouyang H., Migita T., Kato Y., Kimura M., Shiiba K., Sunamura M., Matsuno S., Horii A. The somatic mutation frequency of the transforming growth factor beta receptor type II gene varies widely among different cancers with microsatellite instability. Eur. J. Surg. Oncol. 22:1996;474-477.
175. Akiyama Y., Iwanaga R., Ishikawa T., Sakamoto K., Nishi N., Nihei Z., Iwama T., Saitoh K., Yuasa Y. Mutations of the transforming growth factor-beta type II receptor gene are strongly related to sporadic proximal colon carcinomas with microsatellite instability. Cancer. 78:1996;2478-2484.
176. Ohue M., Tomita N., Monden T., Miyoshi Y., Ohnishi T., Izawa H., Kawabata Y., Sasaki M., Sekimoto M., Nishisho I., Shiozaki H., Monden M. Mutations of the transforming growth factor beta type II receptor gene and microsatellite instability in gastric cancer. Int. J. Cancer. 68:1996;203-206.
177. Lu S.L., Zhang W.C., Akiyama Y., Nomizu T., Yuasa Y. Genomic structure of the transforming growth factor beta type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers. Cancer Res. 56:1996;4595-4598.
178. Konishi M., Kikuchi-Yanoshita R., Tanaka K., Muraoka M., Onda A., Okumura Y., Kishi N., Iwama T., Mori T., Koike M., Ushio K., Chiba M., Nomizu S., Konishi F., Utsunomiya J., Miyaki M. Molecular nature of colon tumors in hereditary nonpolyposis colon cancer familial polyposis and sporadic colon cancer [see comments]. Gastroenterology. 111:1996;307-317.
179. Renault B., Calistri D., Buonsanti G., Nanni O., Amadori D., Ranzani G.N. Microsatellite instability and mutations of p53 and TGF - beta RII genes in gastric cance, r. Human Gen. 98:1996;601-607.
180. Samowitz W.S., Slattery M.L. Transforming growth factor-beta receptor type 2 mutations and microsatellite instability in sporadic colorectal adenomas and carcinomas. Am. J. Pathol. 151:1997;33-35.
181. Chang J., Park K., Bang Y.J., Kim W.S., Kim D., Kim S.J. Expression of transforming growth factor beta type II receptor reduces tumorigenicity in human gastric cancer cells. Cancer Res. 57:1997;2856-2859.
182. Mackay S.L., Auffenberg T., Tannahill C.L., Ksontini R., Josephs M.D., Nowak M., Moldawer L.L., Copeland E.M. 3rd Transfection of the type II TGF - beta receptor into colon cancer cells increases receptor expression inhibits cell growth and reduces the malignant phenotype. Ann. Surg. 227:1998;781-789.
183. Izumoto S., Arita N., Ohnishi T., Hiraga S., Taki T., Tomita N., Ohue M., Hayakawa T. Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas. Cancer Lett. 112:1997;251-256.
184. Takenoshita S., Tani M., Nagashima M., Hagiwara K., Bennett W.P., Yokota J., Harris C.C. Mutation analysis of coding sequences of the entire transforming growth factor beta type II receptor gene in sporadic human colon cancer using genomic DNA and intron primers. Oncogene. 14:1997;1255-1258.
185. Vincent F., Nagashima M., Takenoshita S., Khan M.A., Gemma A., Hagiwara K., Bennett W.P. Mutation analysis of the transforming growth factor-beta type II receptor in human cell lines resistant to growth inhibition by transforming growth factor-beta. Oncogene. 15:1997;117-122.
186. Shitara Y., Yokozaki H., Yasui W., Takenoshita S., Nagamachi Y., Tahara E. Mutation of the transforming growth factor-beta type II receptor gene is a rare event in human sporadic gastric carcinomas. Int. J. Oncol. 12:1998;1061-1065.
187. Rashid A., Hamilton S.R. Genetic alterations in sporadic and Crohn's-associated adenocarcinomas of the small intestine. Gastroenterology. 113:1997;127-135.
188. Garrigue-Antar L., Munoz-Antonia T., Antonia S.J., Gesmonde J., Vellucci V.F., Reiss M. Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells. Cancer Res. 55:1995;3982-3987.
189. Wang D., Song H., Evans J.A., Lang J.C., Schuller D.E., Weghorst C.M. Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck. Carcinogenesis. 18:1997;2285-2290.
190. Orimo H., Ikejima M., Nakajima E., Emi M., Shimada T. A novel missense mutation and frameshift mutations in the type II receptor of transforming growth factor-beta gene in sporadic colon cancer with microsatellite instability. Mutat. Res. 382:1998;115-120.
191. Lynch M.A., Nakashima R., Song H., Degroff V.L., Wang D., Enomoto T., Weghorst C.M. Mutational analysis of the Transforming Growth Factor β receptor type II gene in human ovarian cancer. Cancer Res. 58:1998;4227-4232.
192. Grady W.M., Myeroff L.L., Swinler S.E., Rajput A., Thiagalingam S., Lutterbaugh J.D., Neumann A., Brattain M.G., Chang J., Kim S.J., Kinzler K.W., Vogelstein B., Willson J.K. V., Markowitz S. Mutational inactivation of transforming growth factor-b receptor type II in microsatellite stable colon cancers. Cancer Res. 59:1999;320-324.
193. De M., Yan W., De, Jonge R.R., Garrigue-Antar L., Vellucci V.F., Reiss M. Functional characterization of transforming growth factor beta type II receptor mutants in human cancer. Cancer Res. 58:1998;1986-1992.
194. Knudson J.R., Ag. Heredity cancer oncogenesand antioncogenes. Cancer Res. 45:1985;1437-1443.
195. Akiyama Y., Iwanaga R., Saitoh K., Shiba K., Ushio K., Ikeda E., Iwama T., Nomizu T., Yuasa Y. Transforming Growth Factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer. Gastroenterology. 112:1997;33-39.
196. Grady W.M., Rajput A., Myeroff L., Liu D.F., Kwon K., Willis J., Markowitz S. Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res. 58:1998;3101-3104.
197. Gollerkeri A., Bray-Ward P., Flynn S.D., Reiss M. Allelic loss of transforming growth factor-β receptor genes in primary breast cancer detected by fluorescence in-situ hybridization lab. invest. Proc. Am. Assoc. Cancer Res. 40:1999;134.
198. Lin H.Y., Wang X.F., Ng-Eaton E., Weinberg R.A., Lodish H.F. Expression cloning of the TGF-β type II receptor a functional transmembrane serine/threonine kinase. Cell. 68:1992;775-785.
199. Garrigue-Antar L., Souza R.F., Vellucci V.F., Meltzer S.J., Reiss M. Loss of transforming growth factor-beta type II receptor gene expression in primary human esophageal cancer. Lab. Invest. 75:1996;263-272.
200. Munoz-Antonia T., Li X., Reiss M., Jackson R., Antonia S. A mutation in the transforming growth factor beta type II receptor gene promoter associated with loss of gene expression. Cancer Res. 56:1996;4831-4835.
201. Inagaki M., Moustaka A., Lin H.Y., Lodish H.F., Carr B.I. Growth inhibition by transforming growth factor β (TGF-β) type I is restored in TGF-β-resistant hepatoma cells after expression of TGF-β receptor type II cDNA. Proc. Natl. Acad. Sci. USA. 90:1993;5359-5363.
202. Guo Y., Kyprianou N. Overexpression of transforming growth factor (TGF-) beta1 type II receptor restores TGF - beta1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ. 9:1998;185-193.
203. Derynck R., Zhang Y. Intracellular signalling: The Mad way to do it. Curr. Biol. 6:1996;1226-1229.
204. Macias-Silva M., Abdollah S., Hoodless P.A., Pirone R., Attisano L., Wrana J.L. MADR2 Is a substrate of the TGF - β receptor and its phosphorylation is required for nuclear accumulation and sigaling. Cell. 87:1996;1215-1224.
205. Hayashi H., Abdollah S., Qiu Y., Cai J., Xu Y.Y., Grinnell B.W., Richardson M.A., Topper J.N., Gimbrone Jr M.A., Wrana J.L., Falb D. The MAD-related protein Smad7 associates with the TGF-beta receptor and functions as an antagonist of TGF-beta signaling. Cell. 89:1997;1165-1173.
206. Derynck R., Zhang Y., Feng X.H. Smads Transcriptional activators of TGF - β response, s. Cell. 95:1998;737-740.
207. Zhang Y., Musci T., Derynck R. The tumor suppressor Smad4/DPC4 as a central mediator of Smad function. Curr. Biol. 7:1997;270-276.
208. Zawel L., Dai J.L., Buckhaults P., Zhou S., Kinzler K.W., Vogelstein B., Kern S.E. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol. Cell. 1:1998;611-617.
209. Li J.M., Nichols M.A., Chandrasekharan S., Xiong Y., Wang X.F. Transforming growth factor β activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site. J. Biol. Chem. 270:1995;26750-26753.
210. Elbendary A., Berchuck A., Davis P., Havrilesky L., BastJr R.C., Iglehart J.D., Marks J.R. Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ. 5:1994;1301-1307.
211. Iavarone A., Massagué J. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF - β in cells lacking the CDK inhibitor p15. Nature. 387:1997;417-422.
212. Pietenpol J.A., Munger K., Howley P.M., Stein R.W., Moses H.L. Factor-binding element in the human c-myc promoter involved in transcriptional regulation by transforming growth factor beta 1 and by the retinoblastoma gene product. Proc. Natl. Acad. Sci. USA. 88:1991;10227-10231.
213. Ewen M.E., Sluss H.K., Whitehouse L.L., Livingston D.M. TGF-β inhibition of cdk4 synthesis is linked to cell cycle arrest. Cell. 74:1993;1009-1020.
214. Feng X.H., Filvaroff E.H., Derynck R. Transforming Growth Factor-β (TGF-β)-induced down-regulation of cyclin A expression requires a functional TGF-β receptor complex. J. Biol. Chem. 270:1995;24237-24245.
215. Hata A., Shi Y., Massague J. TGF - beta signaling and cancer structural and functional consequences of mutations in Smads. Mol. Med. Today. 4:1998;257-262.
216. Eppert K., Scherer S.W., Ozcelik H., Pirone R., Hoodless P., Kim H., Tsui L.C., Bapat B., Gallinger S., Rulis I.L., Thomsen G.H., Wrana J.L., Attisano L. MADR2 maps to 18q21 and encodes a TGF-beta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell. 86:1996;543-552.
217. Thiagalingam S., Lengauer C., Leach F.S., Schutte M., Hahn S.A., Overhauser J., Willson J.K., Markowitz S., Hamilton S.R., Kern S.E., Kinzler K.W., Vogelstein B. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat. Genet. 13:1996;343-346.
218. Uchida K., Nagatake M., Osada H., Yatabe Y., Kondo M., Mitsudomi T., Masuda A., Takahashi T. Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. Cancer Res. 56:1996;5583-5585.
219. Riggins G.J., Thiagalingam S., Rozenblum E., Weinstein C.L., Kern S.E., Hamilton S.R., Willson J.K., Markowitz S.D., Kinzler K.W., Vogelstein B. Mad-related genes in the human. Nat. Genet. 13:1996;347-349.
220. Wick W., Petersen I., Schmutzler R.K., Wolfarth B., Lenartz D., Bierhoff E., Hummerich J., Muller D.J., Stangl A.P., Schramm J., Wiestler O.D., VonDeimling A. Evidence for a novel tumor suppressor gene on chromosome 15 associated with progression to a metastatic stage in breast cancer. Oncogene. 12:1996;973-978.
221. Riggins G.J., Kinzler K.W., Vogelstein B., Thiagalingam S. Frequency of Smad gene mutations in human cancers. Cancer Res. 57:1997;2578-2580.
222. Arai T., Akiyama Y., Okabe S., O M., Endo M., Yuasa Y. Genomic structure of the human Smad3 gene and its infrequent alterations in colorectal cancers. Cancer Lett. 122:1998;157-163.
223. Zhao J., Lee M., Smith S., Warburton D. Abrogation of Smad3 and Smad2 or of Smad4 gene expression positively regulates murine embryonic lung branching morphogenesis in culture [In Process Citation]. Dev. Biol. 194:1998;182-195.
224. Takagi Y., Kohmura H., Futamura M., Kida H., Tanemura H., Shimokawa K., Saji S. Somatic alterations of the DPC4 gene in human colorectal cancers in vivo [see comments]. Gastroenterology. 111:1996;1369-1372.
225. Macgrogan D., Pegram M., Slamon D., Bookstein R. Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. Oncogene 15. 1997;1111-1114.
226. Hahn S.A., Schutte M., Hoque A.T., Moskaluk C.A., Da Costa L.T., Rozenblum E., Weinstein C.L., Fischer A., Yeo C.J., Hruban R.H., Kern S.E. DPC4 a candidate tumor suppressor gene at human chromosome 18q21. 1. [see comments]. Science. 271:1996;350-353.
227. Kim S.K., Fan Y., Papadimitrikopoulou V., Clayman G., Hittelman W.N., Hong W.K., Lotan R., Mao L. DPC4 a candidate tumor suppressor gene is altered infrequently in head and neck squamous cell carcinoma. Cancer Res. 56:1996;2519-2521.
228. Nagatake M., Takagi Y., Osada H., Uchida K., Mitsudomi T., Saji S., Shimotaka K., Takahashi T., Takahashi T. Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res. 56:1996;2718-2720.
229. Schutte M., Hruban R.H., Hedrick L., Cho K.R., Nadasdy G.M., Weinstein C.L., Bova G.S., Isaacs W.B., Cairns P., Nawroz H., Sidransky D., CaseroJr R.A., Meltzer P.S., Hahn S.A., Kern S.E. DPC4 gene in various tumor types. Cancer Res. 56:1996;2527-2530.
230. Hahn S.A., Bartsch D., Schroers A., Galehdari H., Becker M., Ramaswamy A., Schwarte-Waldhoff I., Maschek H., Schmiegel W. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res. 58:1998;1124-1126.
231. Howe J.R., Roth S., Ringold J.C., Summers R.W., Jarvinen H.J., Sistonen P., Tomlinson I.P., Houlston R.S., Bevan S., Mitros F.A., Stone E.M., Aaltonen L.A. Mutations in the SMAD4/DPC4 gene in juvenile polyposis [see comments]. Science. 280:1998;1086-1088.
232. LeDai J., Turnacioglu K.K., Schutte M., Sugar A.Y., Kern S.E. Dpc4 transcriptional activation and dysfunction in cancer cells. Cancer Res. 58:1998;4592-4597.
233. Tavtigian S.V., Zabludoff S.D., Wold B.J. Cloning of mid-G1 serum response genes and identification of a subset regulated by conditional myc expression. Mol. Biol. Cell. 5:1994;375-388.
234. Reiss M., Dibble C.L., Narayanan R. Stable transfection of c-myc sequences into mouse keratinocytes amplification of the response to epidermal growth factor. J. Invest. Dermatol. 93:1989;136-141.
235. Alexandrow M.G., Kawabata M., Aakre M., Moses H.L. Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor beta 1. Proc. Natl. Acad. Sci. USA. 92:1995;3239-3243.
236. Khosla S., Oursler M.J., Schroeder M.J., Eberhardt N.L. Transforming growth factor-beta 1 induces growth inhibition of a human medullary thyroid carcinoma cell line despite an increase in steady state c-myc messenger ribonucleic acid levels. Endocrinology. 135:1994;1887-1893.
237. Okamoto A., Jiang W., Kim S.J., Spillare E.A., Stoner G.D., Weinstein I.B., Harris C.C. Overexpression of human cyclin D1 reduces the transforming growth factor beta (TGF - beta) type II receptor and growth inhibition by TGF - beta 1 in an immortalized human esophageal epithelial cell line. Proc. Natl. Acad. Sci. USA. 91:1994;11576-11580.
238. Fero M.L., Rivkin M., Tasch M., Porter P., Carow C.E., Firpo E., Polyak K., Tsai L.H., Broudy V., Perlmutter R.M., Kaushansky K., Roberts J.M. A syndrome of multiorgan hyperplasia with features of gigantism tumorigenesis and female sterility in p27 (Kip1)-deficient mice. Cell. 85:1996;733-744.
239. Missero C., DiCunto F., Kiyokawa H., Koff A., Dotto G.P. The absence of p21Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. Genes Dev. 10:1996;3065-3075.
240. Chung Y.J., Song J.M., Lee J.Y., Jung Y.T., Seo E.J., Choi S.W., Rhyu M.G. Microsatellite instability-associated mutations associate preferentially with the intestinal type of primary gastric carcinomas in a high-risk population. Cancer Res. 56:1996;4662-4665.
241. Gerwin B.I., Spillare E., Forrestier K., Lehman T.A., Kispert J., Welsh J.A., Pfeifer A.M.A., Lechner J.F., Baker S.J., Vogelstein B., Harris C.C. Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor transforming growth factor β1. Proc. Natl. Acad. Sci. USA. 89:1992;2759-2763.
242. Reiss M., Vellucci V.F., Zhou Z.L. Loss of sensitivity to the anti-proliferative effect of Transforming Growth Factor-β1 associated with the expression of mutant p53 tumor suppressor gene in murine keratinocytes. Cancer Res. 53:1993;899-904.
243. Sun P., Dong P., Dai K., Hannon G.J., Beach D. p53-independent role of MDM2 in TGF - beta1 resistance. Science. 282:1998;2270-2272.
244. Benner S.E., Winn R.J., Lippman S.M., Poland J., Hansen K.S., Luna M.A., Hong W.K. Regression of oral leukoplakia with alpha-tocopherol a community clinical oncology program chemoprevention study. J. Natl. Cancer Inst. 85:1993;44-47.
245. Papadimitrakopoulou V.A., Hong W.K., Lee J.S., Martin J.W., Lee J.J., Batsakis J.G., Lippman S.M. Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis long-term follow-up. J. Natl Cancer Inst. 89:1997;257-258.
246. Early Breast, Trialists' Collaborative Group. Early Breast Cancer Trialists' Collaborative Group, Tamoxifen for early breast cancer an overview of the randomised trials, Early Breast Cancer Trialists' Collaborative Group. Lancet. 351:1998;1451-1467.
247. Wolmark N., Dignam J., Fisher B. The addition of tamoxifen to lumpectomy and radiotherapy in the treatment of ductal carcinoma in situ (DCIS) Preliminary results of NSABP protocol B-24. Breast Ca. Res. Treatm. 50:1998;227.
248. Dickens T.A., Colletta A.A. The pharmacological manipulation of members of the transforming growth factor beta family in the chemoprevention of breast cancer. Bioessays. 15:1993;71-74.
249. Bush T.L., Helzlsouer K.J. Tamoxifen for the primary prevention of breast cancer a review and critique of the concept and trial. Epidemiol. Rev. 15:1993;233-243.
250. Powles T.J., Jones A.L., Ashley S.E., O'Brien M.E., Tidy V.A., Treleavan J., Cosgrove D., Nash A.G., Sacks N., Baum M. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res. Treat. 31:1994;73-82.
251. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolmark N. Tamoxifen for prevention of breast cancer report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90:1998;1371-1388.
252. Glick A.B., Flanders K.C., Danielpour D., Yuspa S.H., Sporn M.B. Retinoic acid induces transforming growth factor-beta 2 in cultured keratinocytes and mouse epidermis. Cell. Regul. 1:1989;87-97.
253. Wakefield L., Kim S.J., Glick A., Winokur T., Colletta A., Sporn M. Regulation of transforming growth factor-beta subtypes by members of the steroid hormone superfamily. J. Cell Sci. 13:1990;139-148.
254. Glick A.B., McCune B.K., Abdulkarem N., Flanders K.C., Lumadue J.A., Smith J.M., Sporn M.B. Complex regulation of TGF- beta expression by retinoic acid in the vitamin A-deficient rat. Development. 111:1991;1081-1086.
255. Glick A.B., Sporn M.B., Yuspa S.H. Altered regulation of TGF - beta 1 and TGF - alpha in primary keratinocytes and papillomas expressing v-Ha-ras. Mol. Carcinog. 4:1991;210-219.
256. Batova A., Danielpour D., Pirisi L., Creek K.E. Retinoic acid induces secretion of latent transforming growth factor beta 1 and beta 2 in normal and human papillomavirus type 16-immortalized human keratinocytes. Cell Growth Differ. 3:1992;763-772.
257. Sacco O., Romberger D., Rizzino A., Beckmann J.D., Rennard S.I., Spurzem J.R. Spontaneous production of transforming growth factor-beta 2 by primary cultures of bronchial epithelial cells. Effects on cell behavior in vitro. J. Clin. Invest. 90:1992;1379-1385.
258. Kojima S., Rifkin D.B. Mechanism of retinoid-induced activation of latent transforming growth factor-beta in bovine endothelial cells. J. Cell Physiol. 155:1993;323-332.
259. Danielpour D. Induction of transforming growth factor-beta autocrine activity by all-trans-retinoic acid and 1 alpha25-dihydroxyvitamin D3 in NRP-152 rat prostatic epithelial cells. J. Cell Physiol. 166:1996;231-239.
260. Knabbe C., Lippman M.E., Wakefield L.M., Flanders K.C., Kasid A., Derynck R., Dickson R.B. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell. 48:1987;417-428.
261. Manni A., Wright C., Buck H. Growth factor involvement in the multihormonal regulation of MCF-7 breast cancer cell growth in soft agar. Breast Cancer Res. Treat. 20:1991;43-52.
262. Perry R.R., Kang Y., Greaves B.R. Relationship between tamoxifen-induced transforming growth factor beta 1 expression cytostasis and apoptosis in human breast cancer cells [see comments]. Br. J. Cancer. 72:1995;1441-1446.
263. Murphy L.C., Dotzlaw H. Regulation of transforming growth factor alpha and transforming growth factor beta messenger ribonucleic acid abundance in T-47D human breast cancer cells. Mol. Endocrinol. 3:1989;611-617.
264. Arrick B.A., Korc M., Derynck R. Differential regulation of expression of three transforming growth factor beta species in human breast cancer cell lines by estradiol. Cancer Res. 50:1990;299-303.
265. Koli K.M., Ramsey T.T., Ko Y., Dugger T.C., Brattain M.G., Arteaga C.L. Blockade of transforming growth factor-beta signaling does not abrogate antiestrogen-induced growth inhibition of human breast carcinoma cells. J. Biol. Chem. 272:1997;8296-8302.
266. Colletta A.A., Wakefield L.M., Howell F.V., VanRoozendaal K.E., Danielpour D., Ebbs S.R., Sporn M.B., Baum M. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br. J. Cancer. 62:1990;405-409.
267. Van Roozendaal C.E., Klijn J.G., Van Ooijen B., Claassen C., Eggermont A.M., Henzen-Logmans S.C., Foekens J.A. Transforming growth factor beta secretion from primary breast cancer fibroblasts. Mol. Cell Endocrinol. 111:1995;1-6.
268. Benson J.R., Wakefield L.M., Baum M., Colletta A.A. Synthesis and secretion of transforming growth factor beta isoforms by primary cultures of human breast tumour fibroblasts in vitro and their modulation by tamoxifen. Br. J. Cancer. 74:1996;352-358.
269. Kopp A., Jonat W., Schmahl M., Knabbe C. Transforming growth factor beta 2 (TGF - beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res. 55:1995;4512-4515.
270. Knabbe C., Kopp A., Hilgers W., Lang D., Muller V., Zugmaier G., Jonat W. Regulation and role of TGF- beta production in breast cancer. Ann. NY Acad Sci. 784:1996;263-276.
271. Butta A., Maclennan K., Flanders K.C., Sacks N.P., Smith I., McKinna A., Dowsett M., Wakefield L.M., Sporn M.B., Baum M. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res. 52:1992;4261-4264.
272. Maccallum J., Keen J.C., Bartlett J.M., Thompson A.M., Dixon J.M., Miller W.R. Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy [see comments]. Br. J. Cancer. 74:1996;474-478.
273. Border W.A., Noble N.A. Transforming growth factor β in tissue fibrosis. N. Engl. J. M. 331:1994;1286-1292.
274. Border W.A., Noble N.A. Targeting TGF - beta for treatment of disease. Nature M. 1:1995;1000-1001.
275. Giri S.N., Hyde D.M., Hollinger M.A. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice [see comments]. Thorax. 48:1993;959-966.
276. Giri S.N., Hyde D.M., Braun R.K., Gaarde W., Harper J.R., Pierschbacher M.D. Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis. Biochem. Pharmacol. 54:1997;1205-1216.